US2009053332A1PendingUtilityA1

Compositions for diabetes treatment and prophylaxis

Assignee: AYURVEDIC LIFE INTERNATIONAL LPriority: Aug 11, 2003Filed: Nov 5, 2007Published: Feb 26, 2009
Est. expiryAug 11, 2023(expired)· nominal 20-yr term from priority
A61P 3/10A61P 9/10A61P 3/06C07K 14/415A61K 38/168A61K 31/715A61P 3/04A61K 36/27A61K 36/577
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Gurmarin containing compositions are useful for modulation of glucose metabolism and the treatment of diabetes. Glucose metabolism in a human patient is regulated by isolated gurmarin-containing dosage forms that optionally contain a non-metabolizable polysaccharide such as the exudate of Sterculia urens.

Claims

exact text as granted — not AI-modified
1 . A method for treating a human patient genetically predisposed toward diabetes or suffering from Type I diabetes and receiving insulin therapy, which comprises orally administering to the patient, in an amount and at a frequency sufficient to maintain the patient's blood glucose level at a predetermined value, a composition comprising isolated gurmarin and  Sterculia urens  exudate in a respective weight ratio in a range of about 1:50 to about 1:5. 
     
     
         2 . The method of  claim 1 , wherein the daily dose is in the range of about 100 milligrams to about 600 milligrams. 
     
     
         3 . A method for treating a human patient predisposed toward cholesterolemia, which comprises orally administering to the patient a therapeutically effective amount of the dosage form of a composition comprising isolated gurmarin and  Sterculia urens  exudate in a respective weight ratio in a range of about 1:50 to about 1:5. 
     
     
         4 . A method for treating a human patient predisposed toward obesity, which comprises orally administering to the patient a therapeutically effective amount of a composition comprising isolated gurmarin and  Sterculia urens  exudate in a respective weight ratio in a range of about 1:50 to about 1:5. 
     
     
         5 . A method for treating diabetic retinopathy in a human patient, which comprises orally administering to the patient a therapeutically effective amount of a composition comprising isolated gurmarin and  Sterculia urens  exudate in a respective weight ratio in a range of about 1:50 to about 1:5. 
     
     
         6 . A method for modulating glucose metabolism in a human patient, which comprises orally administering to the patient, in an amount and at a frequency sufficient to maintain the patient's blood glucose level at a predetermined value, a composition comprising isolated gurmarin.

Join the waitlist — get patent alerts

Track US2009053332A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.